It showed that CCMNBs can break through the limitation of universal cancer biomarker recognition, make tumor necrosis factor biomarker targeting not affected by the high heterogeneity of breast cancer tissue, and thus improve the diagnostic ability and potential drug targeting delivery ability (31). This evidence concerns the gene TNF and breast cancer.